Computerized Tremor Analysis of Valproate‐induced Tremor: A Comparative Study of Controlled‐release versus Conventional Valproate
Authors:
Open Access
Abstract
Summary: Purpose: Valproate (VPA) induces postural tremor in 6–45% of patients. The characteristics of VPA‐induced tremor have not yet been quantitatively assessed, and it is not known whether tremor prevalence or severity is affected by VPA formulation (controlled‐release CR‐VPA vs. conventional VPA). The aim of this study was quantitatively to assess tremor in epilepsy patients receiving VPA and to compare the effects of two VPA formulations (CR‐VPA vs. VPA) on tremor severity. Methods: In a prospective study, 18 consecutive patients with newly diagnosed focal or generalized epilepsy were assigned to receive alternately either VPA (n = 10) or CR‐VPA (n = 8) monotherapy. Computerized tremor analysis was performed at baseline 1 day before initiating VPA treatment and repeated after a seizure‐free period of ≥8 weeks, during which VPA doses had remained stable. Rest and postural tremor were recorded by accelerometry, and surface electromyograms (EMGs) were recorded from the wrist flexors and extensors. Results: At baseline, the two groups had similar postural tremor amplitudes. At follow‐up, the CR‐VPA group had remained at the same level, whereas VPA subjects exhibited a significant increase in tremor amplitudes (p < 0.05) despite comparable VPA doses and comparable plasma VPA concentrations at the time of tremor testing. Conclusions: This is the first study to assess quantitatively VPA‐induced tremor by standardized tremor analysis. These results suggest that CR‐VPA may cause less tremorigenic activity as compared with standard VPA. The mechanisms underlying this difference are unclear but may include greater peak–trough variation with VPA than with CR‐VPA.Keywords
This publication has 10 references indexed in Scilit:
- Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsyEpilepsy & Behavior, 2003
- Altered Pharmacokinetics and Metabolism of Valproate after Replacement of Conventional Valproate with the Slow‐Release Formulation in Epileptic PatientsBasic & Clinical Pharmacology & Toxicology, 2002
- Pharmacological and Therapeutic Properties of ValproateCNS Drugs, 2002
- Basic Pharmacology of ValproateCNS Drugs, 2002
- Phenomenology and treatment of tremor disordersNeurologic Clinics, 2001
- Age-Related Prevalence of Platelet-Associated Immunoglobulins G in Nonthrombocytopenic Patients with Autoimmune Thyroid Disease and Autoimmune Polyglandular SyndromeHormone Research in Paediatrics, 2001
- Adverse effects in epilepsy therapy. Wait and see or go for it?Acta Neurologica Scandinavica, 1997
- Assessing tremor severity.Journal of Neurology, Neurosurgery & Psychiatry, 1993
- A comparative clinical and pharmacokinetic study of a new slow-release versus conventional preparations of valproic acid in children with intractable epilepsyBrain and Development, 1992
- Pharmacokinetics of valproic acid and its metabolites after a single oral administration of a sustained-release preparation of sodium valproate (KW-6066N).Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 1988